Pathogens (Oct 2024)

In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (M<sup>pro</sup>)

  • Manuel Alejandro Hernández-Serda,
  • Víctor H. Vázquez-Valadez,
  • Pablo Aguirre-Vidal,
  • Nathan M. Markarian,
  • José L. Medina-Franco,
  • Luis Alfonso Cardenas-Granados,
  • Aldo Yoshio Alarcón-López,
  • Pablo A. Martínez-Soriano,
  • Ana María Velázquez-Sánchez,
  • Rodolfo E. Falfán-Valencia,
  • Enrique Angeles,
  • Levon Abrahamyan

DOI
https://doi.org/10.3390/pathogens13100887
Journal volume & issue
Vol. 13, no. 10
p. 887

Abstract

Read online

The ongoing Coronavirus Disease 19 (COVID-19) pandemic has had a profound impact on the global healthcare system. As the SARS-CoV-2 virus, responsible for this pandemic, continues to spread and develop mutations in its genetic material, new variants of interest (VOIs) and variants of concern (VOCs) are emerging. These outbreaks lead to a decrease in the efficacy of existing treatments such as vaccines or drugs, highlighting the urgency of new therapies for COVID-19. Therefore, in this study, we aimed to identify potential SARS-CoV-2 antivirals using a virtual screening protocol and molecular dynamics simulations. These techniques allowed us to predict the binding affinity of a database of compounds with the virus Mpro protein. This in silico approach enabled us to identify twenty-two chemical structures from a public database (QSAR Toolbox Ver 4.5 ) and ten promising molecules from our in-house database. The latter molecules possess advantageous qualities, such as two-step synthesis, cost-effectiveness, and long-lasting physical and chemical stability. Consequently, these molecules can be considered as promising alternatives to combat emerging SARS-CoV-2 variants.

Keywords